Comera Life Sciences on Developing a New Generation of Biologic Medicines
Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration monoclonal antibody formulations. These self-administered SQ biologics have significant potential benefits over IV infusion for patients and payers. Comera is leveraging its SQore platform in multiple ongoing collaborations with biopharma companies to enhance both commercial biologics and those in early development stages. For more information on Comera Life Sciences, visit https://comeralifesciences.com.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Jeffrey S. Hackman is Chairman and Chief Executive Officer of Comera Life Sciences. Prior to joining Comera, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
